Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Disease-Modifying Antirheumatic Drugs (DMARDs)

Author: Bala K. Nimmana Editor: Preeti Patel Updated: 12/13/2025 10:23:56 PM

Indications

Introduction

Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of therapy for rheumatoid arthritis (RA) and various autoimmune and inflammatory diseases, including psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, and vasculitis. DMARDs are classified into conventional synthetic, biologic, and targeted synthetic DMARDs.[1][2] Although conventional synthetic DMARDs, such as methotrexate, exert broad immunosuppressive effects, biologic and targeted synthetic DMARDs act through the selective inhibition of specific cytokines or cellular pathways.

Unlike symptomatic therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, DMARDs modulate immune mechanisms to suppress inflammation, prevent joint destruction, and maintain remission. Early initiation of DMARDs is associated with improved long-term function and reduced morbidity.[3]

Due to their immunosuppressive potential and monitoring requirements, DMARD therapy necessitates interprofessional coordination. Rheumatologists oversee the selection and titration, whereas primary care providers, pharmacists, and nurses support safety monitoring, immunizations, patient education, and the management of adverse effects.

This review outlines the mechanisms, classifications, indications, pharmacology, and monitoring requirements of DMARDs, emphasizing multidisciplinary collaboration to optimize patient outcomes.

The following classification and indications of Food and Drug Administration (FDA)-approved DMARDs focus primarily on RA. Other indications have been separated for clarity.

Classification of Disease-Modifying Antirheumatic Drugs

  • Conventional synthetic DMARDs: These small-molecule immunomodulators include methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. These DMARDs are often used as first-line treatments due to their cost-effectiveness and established safety profile.
  • Biologic DMARDs: Protein-based agents, such as infliximab, adalimumab, etanercept, rituximab, abatacept, and tocilizumab, target extracellular components, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, CD20, or T-cell costimulatory pathways. These agents are typically reserved for cases refractory to conventional synthetic DMARDs. Among biologic DMARDs used in RA, TNF-α inhibitors form a substantial class, including infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol. Another important category includes B-cell-depleting agents, with rituximab, a monoclonal antibody that targets CD20 on B lymphocytes. T-cell costimulation modulators are represented by abatacept, which inhibits the CD80/CD86-CD28 interaction. Interleukin-6 receptor antagonists include tocilizumab and sarilumab.
  • Targeted synthetic DMARDs: These DMARDs are oral small molecules that inhibit intracellular signaling, particularly JAK-STAT pathways. Examples include tofacitinib, baricitinib, and upadacitinib.[4][5]
  • Biosimilars: These agents offer comparable safety and efficacy to originator biologics, thereby increasing treatment accessibility.
  • Biologic DMARDs are administered parenterally, whereas targeted synthetic DMARDs are oral. Despite their oral route, JAK inhibitors are often grouped with biologics due to their targeted effects and clinical applications.

FDA-Approved Disease-Modifying Antirheumatic Drugs with Indications

Conventional synthetic disease-modifying antirheumatic drugs:

  • Methotrexate: This drug is FDA-approved for use in adults with RA, as indicated in the product labeling. According to the American College of Rheumatology guidelines, methotrexate is strongly recommended over other conventional synthetic DMARDs for DMARD-naive patients with moderate-to-high disease activity.[6]
  • Hydroxychloroquine: This drug is FDA-approved for the acute and chronic RA in adults. The American College of Rheumatology (ACR) 2021 guidelines recommend hydroxychloroquine for patients with low disease activity. Hydroxychloroquine is conditionally recommended over other conventional synthetic DMARDs due to better tolerance and a safer risk profile in patients with RA.[6]
  • Sulfasalazine: This drug is FDA-approved for use in RA with inadequate response to salicylates or other NSAIDs. The ACR 2021 guidelines note that sulfasalazine has less immunosuppressive activity. Thus, the sulfasalazine/hydroxychloroquine trial is reasonable in patients with low disease activity.[6]
  • Lefunomide: Lefunomide is FDA-approved for the treatment of adults with active RA.[7]

Biologic disease-modifying antirheumatic drugs:

  • Etanercept: As per the product label, etanercept is FDA-approved in moderate-to-severe RA to reduce signs and symptoms, achieve significant clinical improvement, slow structural damage progression, and improve physical function.
  • Adalimumab: Adalimumab is FDA-approved in adult patients with moderate-to-severe active RA. Adalimumab alleviates signs and symptoms, inhibits the progression of structural damage, and improves physical function in patients with RA. Adalimumab can be used in combination with methotrexate or other DMARDs.
  • Infliximab: Infliximab, in combination with methotrexate, is FDA-approved for ameliorating signs and symptoms in adults with moderate-to-severe RA. This drug prevents the progression of damage and improves physical function.
  • Golimumab: Golimumab combined with methotrexate is FDA-approved in adult patients with moderate/severe active RA.
  • Certolizumab: Certolizumab is FDA-approved in adult patients with moderate/severe active RA.
  • Abatacept: The T-cell costimulatory inhibitor abatacept is FDA-approved for adult patients with moderate/severe active RA.
  • Tocilizumab: Tocilizumab (IL-6 inhibitor) is FDA-approved for adult patients with moderate/severe active RA with an insufficient response to 1 or more DMARDs. Additionally, it has been approved for COVID-19.
  • Sarilumab: Sarilumab, similar to tocilizumab, is FDA-approved for adult patients with moderate/severe active RA with an insufficient response to 1 or more DMARDs.

Targeted synthetic disease-modifying antirheumatic drugs (JAK inhibitors):

  • Tofacitinib: Tofacitinib extended release is FDA-approved in adults with moderate-to-severe active RA, with unsatisfactory response or intolerance to 1 or more TNF-blockers. However, as per the product label, a combination of tofacitinib with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not advised.
  • Baricitinib: Baricitinib is approved for adult patients with moderate-to-severe active RA who have had an inadequate response to 1 or more TNF blockers.
  • Upadacitinib: Upadacitinib is approved for use in adults with moderate-to-severe RA who have not responded adequately to, or are intolerant of, 1 or more TNF inhibitors. The combination of upadacitinib with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.

Disease-Modifying Antirheumatic Drug Use in Rheumatoid Arthritis: Clinical Role and Evolving Recommendations

RA remains the prototypical condition for DMARD therapy. Methotrexate is the preferred initial agent, as it balances efficacy, safety, and affordability. Treatment is individualized based on disease activity, comorbidities, and patient preference.[8][9]

Current RA management follows a treat-to-target model, with early and aggressive therapy adjustment to achieve remission or low disease activity.[10] Most joint damage occurs within the first few months if left untreated.

The recent ACR 2021 and European Alliance of Associations for Rheumatology (EULAR) 2022 guidelines recommend reserving JAK inhibitors for patients with an inadequate response to biologic DMARDs, particularly those with increased cardiovascular or malignancy risk.[11]

The expanded availability of biosimilars referencing infliximab, adalimumab, and etanercept supports broader access and may influence therapy selection

Indications for Disease-Modifying Antirheumatic Drugs in Other Autoimmune Diseases

DMARDs are indicated for a wide spectrum of autoimmune and inflammatory diseases. Initiation within 3 months of RA symptom onset is critical for achieving remission and preventing irreversible joint damage.[12]

Inflammatory arthritides:

  • Rheumatoid arthritis: Methotrexate is the conventional synthetic DMARD of choice. Non-responders may require combination conventional synthetic DMARD therapy (eg, sulfasalazine and hydroxychloroquine) or escalation to biologic DMARDs or targeted synthetic DMARDs.[13][14][15][16]
  • Psoriatic arthritis: Methotrexate and leflunomide are used for peripheral arthritis; moderate-to-severe cases often require biologics targeting TNF, IL-17, or IL-23.[17][18]
  • Ankylosing spondylitis: Conventional synthetic DMARDs are generally not effective for axial ankylosing spondylitis. Biologics, such as biologic DMARDs, including TNF inhibitors and IL-17 inhibitors, are first-line treatments for NSAID-refractory disease.

Other autoimmune and inflammatory conditions:

  • Systemic lupus erythematosus: Hydroxychloroquine is universally recommended.[19][20] Belimumab and anifrolumab are approved for moderate-to-severe disease.[11]
  • Systemic sclerosis: Methotrexate and mycophenolate mofetil are used to treat skin and lung involvement; IL-6 inhibitors and nintedanib are options for managing interstitial lung disease.[11]
  • Sjögren syndrome: Hydroxychloroquine and methotrexate may be used for systemic manifestations; biologic DMARDs are considered in refractory cases.
  • Idiopathic inflammatory myopathies: Agents include methotrexate, azathioprine, and rituximab for the treatment of polymyositis and dermatomyositis.[21]
  • Vasculitides (eg, granulomatosis with polyangiitis and microscopic polyangiitis): Methotrexate or cyclophosphamide for induction; rituximab is increasingly used. Azathioprine or methotrexate is used for maintenance.
  • Uveitis: Methotrexate and TNF inhibitors for chronic or refractory cases.
  • Inflammatory bowel disease: Azathioprine and methotrexate serve as steroid-sparing agents; TNF, IL-12/23, or integrin inhibitors are used in moderate-to-severe disease.
  • Autoinflammatory syndromes: IL-1 inhibitors (eg, anakinra and canakinumab) are indicated for Still's disease and Behçet's disease.
  • Malignancies: Methotrexate is used in lymphoproliferative disorders and gestational trophoblastic tumors. JAK inhibitors are approved for myelofibrosis and related hematologic malignancies.

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

DMARDs modulate immune responses by targeting pathways involved in chronic inflammation and autoimmunity. These agents suppress pathogenic mechanisms to slow disease progression and reduce tissue damage.

Conventional Synthetic DMARDs

  • Methotrexate enhances extracellular adenosine, which dampens immune activation. This drug also reduces neutrophil adhesion, inhibits leukotriene B4 and cytokine (IL-1, IL-6, and IL-8) production, and downregulates synovial collagenase expression, leading to broad anti-inflammatory effects.[22][23][24]
  • Leflunomide blocks dihydroorotate dehydrogenase, thereby inhibiting pyrimidine synthesis and suppressing the proliferation of activated lymphocytes.[25]
  • Sulfasalazine reduces inflammation by inhibiting cytokine release, scavenging reactive oxygen species, and potentially modulating adenosine signaling.
  • Hydroxychloroquine modulates innate immunity by raising lysosomal pH and inhibiting toll-like receptor (TLR7 and TLR9) signaling, thus impairing antigen presentation and cytokine release.[26][27]

Although each conventional synthetic DMARD has distinct molecular targets, all aim to suppress immune activation and cytokine-driven inflammation.

Biologic DMARDs

Biologic agents are engineered proteins that selectively modulate extracellular immune pathways by targeting cytokines, immune cells, or costimulatory signals:

  • TNF inhibitors (eg, etanercept, adalimumab, infliximab, golimumab, and certolizumab) neutralize TNF-α, a central driver of synovial and systemic inflammation.[6]
  • IL-6 inhibitors (eg, tocilizumab and sarilumab) block the IL-6 receptor, suppressing downstream inflammatory cascades.
  • IL-1 inhibitors (eg, anakinra) inhibit early innate immune activation by blocking IL-1 signaling.
  • Abatacept is classified as a costimulatory inhibitor. This drug inhibits CD80/CD86-CD28 interaction, preventing full T-cell activation by blocking the required second costimulatory signal.[28][29]
  • Rituximab targets CD20 on B cells, leading to their depletion and a reduction in autoantibody production and antigen presentation.
  • Biologics may be monoclonal antibodies (fully human, chimeric, or humanized) or fusion proteins combining receptor elements with immunoglobulin domains to enhance specificity and durability.

Targeted Synthetic DMARDs

Targeted synthetic DMARDs are oral small molecules that disrupt intracellular signaling, particularly cytokine pathways.

  • Tofacitinib inhibits JAK enzymes, disrupting JAK-STAT–mediated cytokine signaling and transcription.[26][30][31]
  • Baricitinib and upadacitinib act similarly but differ in JAK isoform selectivity and pharmacokinetics.

By blocking these intracellular signals, targeted synthetic DMARDs suppress the expression of immune genes central to autoimmunity.

Administration

DMARS: Formulations, Dosages, and Strengths

DMARD selection should consider drug properties, disease severity, comorbidities, adherence potential, and monitoring requirements. The route of administration—oral, subcutaneous (SC), or intravenous (IV)—impacts efficacy, treatment burden, and patient preference.

  • Conventional synthetic DMARDs: Methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine are primarily oral. Methotrexate may also be administered SC at higher doses to improve bioavailability and reduce gastrointestinal intolerance.[24][32][33]
  • Targeted synthetic DMARDs: Tofacitinib, baricitinib, and upadacitinib are oral small-molecule inhibitors.
  • Biologic DMARDs require parenteral administration. SC agents include etanercept, adalimumab, sarilumab, abatacept, and tocilizumab. IV agents include infliximab, rituximab, abatacept, and tocilizumab. Route selection influences access, infusion reactions, and monitoring logistics.

Monitoring: SC methotrexate reduces gastrointestinal adverse effects but requires routine liver and hematologic testing. IV biologics may require premedication and monitored infusion to manage reactions.[34]

Routes of Administration

  • Oral: Methotrexate (also SC), leflunomide, hydroxychloroquine, sulfasalazine, JAK inhibitors (tofacitinib, baricitinib, upadacitinib), and apremilast.
  • SC: Etanercept, adalimumab, sarilumab, abatacept (also IV), and tocilizumab (also IV).
  • IV: Infliximab, rituximab, abatacept, and tocilizumab

Initial Management in Rheumatoid Arthritis

RA treatment employs a treat-to-target approach, aiming for remission or low disease activity. The American College of Rheumatology recommends initiating DMARDs within 3 months of symptom onset.[6][35]

Initial Therapy:

  • Methotrexate: First-line agent for moderate-to-high disease activity. Initiated at 7.5 to 15 mg weekly, titrated to 25 mg/week. SC route enhances efficacy at higher doses.
  • Hydroxychloroquine: Approximately 200 to 400 mg/d for mild disease; requires ophthalmologic monitoring for retinal toxicity.
  • Sulfasalazine: Up to 3 g/d in divided doses; used as monotherapy or in combination.
  • Leflunomide: 20 mg/d; requires cholestyramine washout before conception due to long half-life.

Escalation Strategy

If goals are not achieved after approximately 3 months:

  • Maximize current conventional synthetic DMARD dosing
  • Initiate a combination of conventional synthetic DMARDs
  • Escalate to a biologic or targeted synthetic DMARD based on disease profile, safety, and patient factors.

Biologic DMARDs

  • Infliximab is administered IV at an initial dose of 3 mg/kg at weeks 0, 2, and 6, followed by maintenance dosing every 8 weeks. The dose may be increased to 10 mg/kg or administered more frequently (as often as every 4 weeks) in patients with an insufficient response.
  • Adalimumab is given SC at 40 mg every other week. In patients not receiving methotrexate, some may benefit from 40 mg every week.
  • Etanercept is administered SC at a dose of 50 mg once weekly.
  • Rituximab is administered as 2 IV infusions of 1000 mg, separated by 2 weeks. Subsequent courses may be repeated based on clinical evaluation, provided that no more than every 16 weeks. Abatacept can be administered IV based on body weight at 0, 2, and 4 weeks, then every 4 weeks thereafter. The SC dose is 125 mg once weekly, starting the day after an optional IV loading dose.
  • Tocilizumab may be given IV or SC. The IV dose is 4 mg/kg every 4 weeks, which may be increased to 8 mg/kg. The SC dose is 162 mg weekly (for <100 kilograms) or every other week (for ≥100 kg); some patients may need weekly dosing for a complete response.

Targeted synthetic DMARDs

  • Tofacitinib is taken orally at 5 mg twice daily, or 11 mg once daily in the extended-release form.
  • Baricitinib is administered at 2 mg once daily; in some cases, 4 mg daily may be used based on disease severity and risk-benefit assessment.
  • Upadacitinib is given orally at 15 mg once daily based on disease severity and risk-benefit assessment.

Specific Patient Populations

Pregnancy considerations: DMARD use during pregnancy and lactation requires coordinated care to ensure maternal disease control and fetal/infant safety. General compatible drugs are given below. Please refer to the individual monograph for accurate information and make a shared decision.

  • Hydroxychloroquine is safe and recommended in systemic lupus erythematosus; it reduces flares with no fetal ocular toxicity.[36][37]
  • Sulfasalazine is safe with ≥2 mg/d folic acid; may rarely cause neonatal jaundice near term.
  • Azathioprine, colchicine, calcineurin inhibitors, and low-dose prednisone (≤10 mg/d) are acceptable when needed.[38]

Biologics:

  • Certolizumab pegol is preferred for anti-TNF therapy due to minimal placental transfer.[39][40]
  • Adalimumab and etanercept may be continued into the second trimester; use in the third trimester is individualized.[40]
  • Live vaccines should be delayed in infants exposed to biologics in late pregnancy.[41]

These medications are generally avoided during pregnancy:

  • Methotrexate: Discontinue ≥1 cycle before conception (women); ≥3 months in men.
  • Leflunomide: Requires cholestyramine washout and confirmed plasma clearance.
  • Mycophenolate, cyclophosphamide, and JAK inhibitors are contraindicated.[42]

Breastfeeding Considerations:

Compatible:

  • Hydroxychloroquine, sulfasalazine, azathioprine, colchicine, NSAIDs, calcineurin inhibitors, and TNF inhibitors are considered generally safe.[38] However, any change in specific product label data, recent change in recommendations due to new research or guidelines, and shared decision-making according to institutional protocols are essential. For biologics, certolizumab is considered safe due to its negligible excretion into breast milk. Other biologics, such as adalimumab and etanercept, are found in breast milk at very low levels and may be used with caution, weighing the risks and benefits.
  • Prednisone ≤20 mg/d is safe; for higher doses, breastfeeding should be delayed for ≥4 hours.[43]

Avoid:

  • Methotrexate, leflunomide, and JAK inhibitors should be avoided due to their cytotoxicity and insufficient safety data.[38]
  • JAK inhibitors, including tofacitinib, baricitinib, and upadacitinib, are not recommended for use during pregnancy, with animal studies showing evidence of fetal harm. These agents should only be used if the potential benefit justifies the potential risk to the fetus. In general, non-TNF biologics can be used cautiously if the benefits outweigh the risks.[38]

Paternal Exposure

  • Methotrexate should be discontinued at least 3 months before conception.[44]
  • Leflunomide requires washout and plasma clearance confirmation in either partner.[38]

Hepatic Impairment

  • Methotrexate is contraindicated in patients with alcoholic liver disease or chronic liver disease due to its significant hepatotoxicity risk.[45] Leflunomide requires caution, with a dose reduction or avoidance recommended in hepatic dysfunction.[46] 
  • Hydroxychloroquine has no specific hepatic adjustments, though hepatotoxicity is a rare reported adverse effect. 
  • Among biologics, TNF inhibitors (adalimumab, infliximab, etanercept, certolizumab, golimumab) and IL inhibitors (tocilizumab, anakinra, secukinumab) generally do not require dose adjustments but warrant caution because hepatotoxicity has been reported. Tocilizumab has warnings for liver enzyme elevation.[47] JAK inhibitors, including tofacitinib, baricitinib, and upadacitinib, require dose adjustment or avoidance in moderate/severe hepatic impairment due to their altered metabolism and increased drug exposure in these patients.[48][49]

Renal Impairment

  • Methotrexate clearance is significantly reduced in patients with renal impairment, making dose reduction essential. This drug is contraindicated in severe renal dysfunction (CrCl < 30 mL/min). Data for leflunomide are limited, and the drug is generally avoided in severe renal disease. Sulfasalazine should be used with caution, as crystalluria and nephrotoxicity have been reported.
  • Most biologics, such as adalimumab, infliximab, and etanercept, do not require dose adjustments. However, anakinra is an exception, requiring a dose adjustment for patients with a creatinine clearance below 30 mL/min.[50]
  • Among JAK inhibitors, baricitinib requires dose adjustments in moderate and severe renal impairment and is not recommended for patients with end-stage renal disease. Tofacitinib also requires a dose reduction in moderate-to-severe renal impairment. Upadacitinib is not recommended for patients with end-stage renal disease or severe renal impairment.

Pediatric Patients

  • The primary application of DMARDs in pediatric patients is for juvenile idiopathic arthritis (JIA). Methotrexate is a cornerstone of treatment for JIA. Leflunomide, sulfasalazine, and hydroxychloroquine are also used in pediatric patients, requiring careful weight-based dosing and monitoring.
  • For biologics, several have specific pediatric approvals for JIA, including etanercept, adalimumab, and tocilizumab. Certolizumab and golimumab are also approved for polyarticular JIA. The JAK inhibitor tofacitinib is approved for polyarticular JIA in patients aged 2 or older, and upadacitinib has also received approval for JIA in a similar age group.

Older Adults 

  • All DMARDs and biologics require special caution in older adults, who often have comorbidities. Methotrexate, leflunomide, and azathioprine necessitate dose adjustments based on renal/hepatic function. Sulfasalazine and hydroxychloroquine are better tolerated; however, healthcare providers must remain vigilant for gastrointestinal adverse effects with sulfasalazine and retinal toxicity with hydroxychloroquine.
  • Biologics do not typically require specific dose adjustments in older adults, but their use is associated with a higher risk of serious infections. Both tocilizumab and TNF inhibitors should be used with caution in this population due to the increased risk of infections and malignancies. JAK inhibitors carry a higher risk of serious infections, major adverse cardiovascular events, venous thromboembolism, and malignancy in older adults, particularly those older than 65, and thus should be used with extreme caution.[51]

Adverse Effects

DMARDs, particularly biologics and high-dose conventional agents, suppress immune function, thereby increasing the risk of infection. Adverse effects vary by agent and may involve gastrointestinal, hepatic, hematologic, pulmonary, neurologic, dermatologic, infectious, reproductive, or oncologic systems. Ongoing monitoring and individualized risk assessment are essential.

Hydroxychloroquine

  • Well-tolerated, with minimal infection, hepatic, or bone-marrow toxicity.
  • Ocular: Retinal toxicity (maculopathy) is rare; the risk increases with doses >5 mg/kg/d dosing or with use beyond 5 years.[52][53][54] Annual eye examinations are recommended after 5 years of therapy, or earlier in patients at high risk.
  • Other rare effects: Myopathy, cardiomyopathy, anemia, and leukopenia.

Methotrexate

  • Gastrointestinal: Nausea, stomatitis, mucositis, and diarrhea.
  • Hepatic: Elevated transaminases, steatosis, fibrosis, or cirrhosis—worsened by alcohol, viral hepatitis, or MASLD.[55]
  • Pulmonary: Acute interstitial pneumonitis and fibrosis.[56]
  • Hematologic: Macrocytic anemia, leukopenia, thrombocytopenia, and pancytopenia, especially in chronic kidney disease or with daily dosing errors.
  • Neurologic: Headache, fatigue, and cognitive symptoms.
  • Infectious: Mild infection risk; rare pneumocystis pneumonia with corticosteroids or biologics.[57]
  • Reproductive/oncologic: Teratogenic; linked to reversible Epstein-Barr virus–related lymphoproliferation.
  • Other: Nodulosis, osteopenia, reduced vaccine efficacy, and rare skin cancers.
  • Prevention: Folic acid reduces the incidence of mucositis and cytopenias.[58] A complete blood count (CBC) and liver function tests (LFTs) should be monitored; hepatitis screening is also recommended. Additionally, a chest radiograph is recommended. Therapy should be withheld during infections.

Sulfasalazine

  • Hypersensitivity: Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatitis, pneumonitis, and agranulocytosis.[59]
  • Dose-related: Nausea, macrocytosis, and leukopenia—typically reversible.
  • Liver/bone marrow: The risk increased with etanercept.
  • Reproductive: Reversible oligospermia; safe in pregnancy.
  • Other: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), Epstein-Barr virus hypersensitivity, and encephalopathy; greater toxicity in slow acetylators.

Leflunomide

  • Gastrointestinal/liver: Diarrhea, nausea, and transaminitis; rare hepatic failure (higher risk with methotrexate or alcohol).[60]
  • Lung/cardio: Hypertension, interstitial lung disease—avoid if preexisting lung disease.
  • Skin/nerve: Rash, alopecia, and neuropathy; rare Stevens-Johnson syndrome.
  • Hematologic: Cytopenias, especially with methotrexate; potentiates warfarin.
  • Other: Teratogenic—requires cholestyramine washout before conception. CYP polymorphisms affect metabolism.

TNF Inhibitors

  • Infusion/site reactions: Especially common with infliximab.
  • Infections: Tuberculosis, hepatitis B reactivation, and bacterial/fungal infections.[61]
  • Neurologic/cardiac: Demyelination, congestive heart failure exacerbation (NYHA class III/IV), and rare interstitial lung disease.[62]
  • Skin/liver: Psoriasiform rashes and mild transaminitis.
  • Malignancy: Associated with lymphoma and non-melanoma skin cancer.[63]
  • Monitoring: Tuberculosis and hepatitis should be screened for; CBC and LFTs should be monitored; an echocardiogram should be obtained if there is a risk of heart failure.

Rituximab

  • Infusion: First-dose reactions are common; rare cases of anaphylaxis have been reported.
  • Infections: Pneumocystis jirovecii pneumonia, cytomegalovirus, and progressive multifocal leukoencephalopathy (PML).[64]
  • Hematologic: Late-onset neutropenia, hypogammaglobulinemia, and hepatitis B reactivation.
  • Monitoring: CBC, renal/hepatic panels, C-reactive protein/erythrocyte sedimentation rate, and immunoglobulin levels should be monitored. Pneumocystis pneumonia prophylaxis should be considered.

JAK Inhibitors

  • Common: Headache, nausea, respiratory, or urinary infections.
  • Severe infections: Herpes zoster, tuberculosis, and fungal infections.
  • Boxed Warning: Elevated risk of serious infections, major adverse cardiovascular events, malignancy, and venous thromboembolism.
  • Gastrointestinal: LFT elevations and rare gastrointestinal perforation.[65]
  • Other: Cytopenias, Reports of lymphoma, and lung cancer; filgotinib may impair sperm production.
  • Monitoring: CBC, LFTs, lipids, and cardiovascular/thrombotic risk should be monitored.

Drug-Drug Interactions

DMARDs are associated with clinically significant drug-drug interactions that may alter drug metabolism, increase toxicity, or reduce therapeutic efficacy. These risks are elevated in older adults, patients with renal or hepatic dysfunction, and those with polypharmacy. Careful medication reconciliation and proactive monitoring are essential to minimize harm.

Methotrexate

  • Renally cleared agents such as NSAIDs, proton pump inhibitors, sulfasalazine, and amoxicillin impair methotrexate excretion, increasing the risk of hepatotoxicity, cytopenias, and mucositis.[66]
  • Trimethoprim-sulfamethoxazole is contraindicated due to synergistic antifolate effects, which can lead to severe bone marrow suppression.[67][68]
  • Alcohol use potentiates hepatotoxicity and should be avoided.
  • Cyclosporine may enhance nephrotoxicity through metabolic competition.

Leflunomide

  • Teriflunomide inhibits warfarin metabolism; international normalized ratio monitoring is required.
  • Rifampin induces CYP enzymes, thereby accelerating leflunomide clearance and reducing the drug's efficacy.
  • Co-administration with methotrexate increases the risk of hepatotoxicity and bone marrow suppression.

Sulfasalazine

  • Sulfasalazine inhibits folate absorption, which may potentially enhance methotrexate toxicity; therefore, folic acid supplementation is recommended.
  • Sulfasalazine displaces thiopurines (eg, azathioprine and 6-mercaptopurine) from protein-binding sites, increasing the risk of hematologic toxicity.

Hydroxychloroquine

  • Hydroxychloroquine can increase digoxin levels, worsen hypoglycemia when combined with antidiabetic agents, and lower seizure threshold when used with antiepileptics.[69]

Cyclosporine

  • Cyclosporine levels increase when taken with CYP3A4 inhibitors (eg, azoles, macrolides, and calcium channel blockers), thereby raising the risk of nephrotoxicity.
  • Co-administration with statins or fibrates increases the risk of myopathy and rhabdomyolysis.[70]
  • Concomitant NSAID use may worsen renal function.

Biologic DMARDs and JAK Inhibitors

  • Combining multiple biologic agents or a biologic with a JAK inhibitor is contraindicated due to the risk of profound immunosuppression and severe infections.
  • Live vaccines are contraindicated in patients receiving biologic DMARDs or high-dose methotrexate.
  • JAK inhibitors require dosage adjustment when used with potent CYP3A4 modulators (eg, ketoconazole and rifampin).
  • Clinical note: Only 1 biologic or targeted agent (eg, JAK inhibitor) should be used at a time. Combination with conventional DMARDs is standard and considered safe.[71]

Comorbidities and Polypharmacy Considerations

  • NSAIDs may worsen nephrotoxicity with methotrexate or cyclosporine.
  • Proton pump inhibitors impair methotrexate elimination, potentially increasing systemic exposure.
  • Warfarin requires close monitoring of the international normalized ratio when used in combination with leflunomide.
  • Hydroxychloroquine may induce hypoglycemia with antidiabetic agents; corticosteroids may blunt antidiabetic efficacy.
  • Routine assessment of renal and hepatic function, medication review, and interprofessional coordination are critical, particularly in high-risk patients.

Contraindications

DMARD contraindications vary by agent and are informed by ACR and EULAR guidelines. Key contraindications include:

  • Active infections: Biologic and targeted synthetic DMARDs should be avoided in patients with untreated tuberculosis, herpes zoster, or systemic infections. Therapy should be withheld until resolution.
  • Latent tuberculosis: Must be screened and treated before initiating biologics.
  • Cytopenias: Immunosuppressive DMARDs are contraindicated in neutropenia, thrombocytopenia, or marrow failure.
  • Hepatic impairment: Methotrexate and leflunomide are contraindicated in patients with significant liver dysfunction or elevated transaminases.[55]
  • Renal impairment (estimated glomerular filtration rate <30 mL/min): Methotrexate requires dose adjustment or discontinuation.[72] 
  • Pregnancy/lactation: Methotrexate and leflunomide are contraindicated.[22]
  • Heart failure (NYHA class III-IV): TNF inhibitors are contraindicated due to the risk of worsening cardiac function.
  • Demyelinating disease: TNF inhibitors may exacerbate multiple sclerosis and similar conditions.
  • Malignancy: Biologic and targeted synthetic DMARDs should be individualized based on cancer history and risk.
  • Gastrointestinal perforation risk: IL-6 and JAK inhibitors require caution in diverticulitis.[73]
  • Neuropsychiatric illness: Apremilast is contraindicated in active depression or suicidality.[74]
  • Live vaccines: Contraindicated during therapy with biologic DMARDs, targeted synthetic DMARDs, and high-dose methotrexate. Vaccination should precede initiation.[75]

Baseline evaluation should include CBC, liver/renal panels, hepatitis serologies, tuberculosis screening, and pregnancy testing in women of childbearing potential. Ongoing monitoring is required throughout therapy.

Box Warnings

TNF-alpha inhibitors:

  • TNF inhibitors increase the risk of serious infections, including tuberculosis, invasive fungal infections, bacterial sepsis, and other opportunistic infections, which may be fatal. Patients should be screened for latent tuberculosis before initiating TNF inhibitor therapy.
  • These agents have been associated with an increased risk of lymphoma and other malignancies, particularly in pediatric and adolescent patients. Rare cases of hepatosplenic T-cell lymphoma, which is often fatal, have been reported in young males receiving TNF blockers. The development of melanoma and non-melanoma skin cancers has been reported during treatment, and patients should undergo regular dermatologic evaluations.

IL-6 antagonists:

  • IL-6 antagonists can cause serious infections, including tuberculosis, bacterial, viral, and fungal infections, which may require hospitalization or prove fatal. Patients must be screened for latent tuberculosis before starting therapy with IL-6 inhibitors. Treatment should be withheld if a patient develops a severe infection during therapy.

JAK inhibitors:

  • JAK inhibitors are associated with a risk of serious infections, including tuberculosis and opportunistic infections, which may be fatal. These agents have demonstrated increased mortality in patients aged 50 or older who have at least 1 cardiovascular risk factor. There is an increased risk of malignancies, including lymphoma and lung cancer, particularly among current or former smokers.
  • Major adverse cardiovascular events, such as myocardial infarction, stroke, and cardiovascular death, have been observed in patients with risk factors. JAK inhibitors increase the risk of thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, which can be life-threatening. Baseline screening for tuberculosis, hepatitis B virus, and personal cancer history is essential before starting therapy.

Rituximab:

  • Fatal infusion-related reactions have occurred within 24 hours of the first infusion and require immediate medical intervention. Rituximab may cause severe mucocutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which may be life-threatening. 
  • PML, a rare and typically fatal central nervous system infection caused by John Cunningham virus reactivation, has been reported in patients treated with rituximab. Hepatitis B virus reactivation may occur, potentially leading to fulminant hepatitis, hepatic failure, and death; all patients should be screened before initiation. Patients should be closely monitored during and after the infusion for signs of severe reactions. 

Methotrexate:

  • Methotrexate can cause embryo-fetal toxicity and is contraindicated in pregnancy due to its teratogenic effects. The drug may cause bone marrow suppression, resulting in anemia, leukopenia, and thrombocytopenia, which can be life-threatening. Methotrexate carries a risk of hepatotoxicity, including fibrosis and cirrhosis, even with short-term use. Pulmonary toxicity, such as interstitial pneumonitis, may occur unpredictably and can be fatal, irrespective of dose.
  • High-dose methotrexate can lead to acute renal failure and requires close monitoring of renal function. Methotrexate increases the risk of serious infections, particularly in immunocompromised individuals or those receiving concomitant immunosuppressive therapy. Gastrointestinal toxicity, including ulcerative stomatitis and diarrhea, may progress to hemorrhagic enteritis and death. Long-term use has been associated with secondary malignancies, including lymphoma.

Leflunomide:

  • Leflunomide can cause embryo-fetal toxicity and hepatotoxicity. This drug is contraindicated in pregnant women due to its teratogenicity and embryo-lethal effects. Pregnancy must be excluded before treatment, and effective contraception is advised during and after therapy until the drug is eliminated through an accelerated procedure.
  • Leflunomide is associated with severe hepatotoxicity, including fatal liver failure. This drug is contraindicated in patients with severe hepatic impairment and should not be used in individuals with increased liver enzymes or pre-existing liver disease. Monthly LFT monitoring is recommended for the first 6 months, followed by testing every 6 to 8 weeks. If hepatotoxicity is suspected, leflunomide should be stopped, and drug elimination procedures initiated.[46]

Monitoring

DMARDs include conventional, biologic, and targeted synthetic agents, which require individualized monitoring due to risks such as hepatotoxicity, cytopenias, nephrotoxicity, infections, hyperlipidemia, and retinal toxicity.

Baseline Evaluation

Before initiation, the following assessments are recommended:

  • CBC, LFTs, and renal function (creatinine and estimated glomerular filtration rate)
  • Hepatitis B/C serologies and tuberculosis screening
  • HIV testing in high-risk individuals
  • Immunization review: Update inactivated vaccines (eg, influenza, pneumococcus, and COVID-19); administer recombinant zoster vaccine if eligible; avoid live vaccines once therapy begins.[75]
  • Pregnancy testing and contraceptive counseling in women initiating teratogenic agents (eg, methotrexate and leflunomide).[76][38][76]

General Principles

Monitoring should be more frequent during the first 3 to 6 months, with intervals extended during stable maintenance therapy. Frequency should be tailored to age, comorbidities, renal/hepatic function, and concurrent medications.[12]

Ongoing Monitoring

Disease activity should be reassessed every 1 to 3 months using validated tools. The tools used are the DAS28 (Disease Activity Score 28) and the CDAI (Clinical Disease Activity Index).[6][77]If remission or low activity is sustained for at least 6 months, tapering may be considered in conjunction with shared decision-making. Long-term planning should incorporate comorbidities, flare risk, treatment burden, and patient values.

Effective RA care requires interprofessional collaboration to ensure:

  • Timely therapy adjustment
  • Ongoing safety monitoring
  • Enhanced adherence
  • Durable outcomes

Agent-Specific Monitoring

  • Methotrexate
    • CBC, LFTs, creatinine: Baseline; initially every 2-4 weeks, then every 8-12 weeks, and then every 12 weeks once stable.
    • Renal function: Monitor every 3-6 months.
    • In high-risk patients (eg, diabetes mellitus and metabolic dysfunction-associated steatotic liver disease), consider non-invasive evaluation of hepatic fibrosis.[78][79]
    • In patients with a prior history of pulmonary disease, consider obtaining a baseline chest x-ray due to the possibility of methotrexate induced pulmonary toxicity, including pneumonitis.[80][81][82][80]
  • Leflunomide and sulfasalazine
    • CBC, LFTs, creatinine: Baseline; every 4-8 weeks during initiation; every 3-4 months thereafter.
  • Hydroxychloroquine
    • Baseline ophthalmologic exam with optical coherence tomography.[83]
    • Annual screening after 5 years or earlier in high-risk individuals (eg, dose >5 mg/kg/d, renal disease, and older age).
    • CBC and LFTs every 6-12 months.
  • Biologic and targeted synthetic DMARDs (eg, TNF, IL-6, and JAK inhibitors)
    • CBC and LFTs: Baseline and every 3–6 months.
    • Lipids: Baseline, repeat at 8-12 weeks, then every 6 months in patients on IL-6 or JAK inhibitors.[84]
    • Tuberculosis screening: Before initiation; repeat annually in high-risk populations.
    • Hepatitis B: Viral load monitoring in anti-HBc–positive patients on prophylaxis.

Clinical Vigilance

Monitor for non-laboratory signs of toxicity, such as thrombosis, infections, lymphadenopathy, and metabolic changes, especially with JAK inhibitors.

Management of Abnormal Results

Significant abnormalities (eg, transaminitis, cytopenias, and renal decline) may necessitate dose adjustment or drug discontinuation. Specialist referral should be considered for persistent abnormalities.

Summary

DMARD monitoring must be comprehensive and risk-adapted. Baseline laboratory parameters, infection screening, vaccination, and ongoing surveillance are essential. Patient education on adverse effects, contraception, and vaccination optimizes safety and therapeutic success.

Toxicity

Toxicity from DMARDs is agent-specific and influenced by dosing, administration route, and comorbid conditions such as renal or hepatic impairment. Management depends on the severity and organ involvement, with specific agents requiring targeted interventions.

Methotrexate

Low-dose methotrexate may cause mucositis, hepatotoxicity, and cytopenias, particularly in renal dysfunction or dosing errors. High-dose oncologic use is associated with severe pancytopenia and transaminitis.[85]

  • Leucovorin is used to mitigate the toxicity of antifolates.[86]
  • Glucarpidase is reserved for severe toxicity with delayed clearance in renal failure, but it is uncommon in rheumatology dosing.[87]

Leflunomide

The active metabolite of leflunomide, teriflunomide, has a prolonged half-life.

  • Cholestyramine washout (8 g TID for 11 days) accelerates elimination.[60]

Undetectable plasma levels are advised before conception in both sexes.

Sulfasalazine

Overdose is rare; toxicity may present as hypersensitivity, hepatotoxicity, or cytopenias.[88]

  • Management is supportive, with no specific antidote.

Biologic DMARDs

The primary risks include immunosuppression and infection (eg, tuberculosis, pneumonia, and herpes zoster).[89]

  • Therapy should be discontinued during an active infection and resumed after resolution.
  • Rituximab has been associated with rare cases of PML; no antidote exists.[90]

Prompt, individualized toxicity management is essential. Preventive measures, including patient education and monitoring, reduce risk, especially in those with renal or hepatic impairment or polypharmacy. For up-to-date recommendations, consultation with a medical toxicologist or the poison control center is advised.

Enhancing Healthcare Team Outcomes

 Pearls and Pitfalls 

  • Early DMARD initiation improves outcomes: Starting within 3 months of RA onset reduces joint damage and preserves function.
  • Methotrexate remains the first-line treatment: Weekly dosing with folic acid is standard; SC administration may enhance tolerance and efficacy.
  • Hydroxychloroquine is well tolerated: Safe in pregnancy; requires baseline and periodic eye examinations to detect retinal toxicity.
  • Certolizumab is preferred during pregnancy: Minimal placental transfer makes it the safest biologic option.
  • Infection screening is essential: Screen for tuberculosis and hepatitis B before starting biologics or JAK inhibitors.
  • JAK inhibitors carry boxed warnings: Use cautiously in refractory disease due to increased risks of thrombosis, malignancy, and cardiovascular events.
  • Leflunomide requires drug elimination before conception: Cholestyramine washout is needed for both men and women.
  • Patient education is critical: Reinforce adherence, lab follow-up, and early reporting of symptoms such as fever or cough.
  • Pharmacist and nurse involvement enhances patient safety: Support proper dosing, laboratory coordination, and patient counseling.

Common Pitfalls

  • Omitting baseline laboratory parameters or vaccine review increases preventable risks.
  • Using methotrexate in advanced chronic kidney disease without adjustment may lead to severe toxicity.
  • The combination of methotrexate with trimethoprim-sulfamethoxazole may result in severe bone marrow suppression.
  • Delaying infection screening before immunosuppressive therapy may result in reactivation.
  • Assuming all biologics are safe in pregnancy is incorrect; only certolizumab has established safety.
  • Neglecting eye exams while taking hydroxychloroquine can delay the detection of retinal toxicity.
  • Restarting biologics too soon after infection may worsen clinical outcomes.
  • Inadequate early monitoring misses adverse effects that commonly occur within the first 3 to 6 months.

Effective DMARD therapy requires coordinated interprofessional care to ensure safe monitoring, early detection of toxicity, and optimized treatment outcomes. Rheumatologists initiate and adjust therapy, monitor disease activity, and manage the risks associated with immunosuppression. Primary care providers address comorbidities, support vaccination, and assist with infection screening. Pharmacists assess for drug interactions, confirm dosing accuracy, and counsel on adverse effect prevention. Nurses administer therapy, monitor for complications, reinforce patient education, and provide ongoing follow-up care. Patients and caregivers contribute through adherence, symptom reporting, and contraceptive compliance when applicable. This interprofessional team approach, combined with clear communication among physicians, advanced practice providers, nurses, and pharmacists, decreases adverse effects and improves patient outcomes related to DMARDs.

References

[1]

Patel JP, Konanur Srinivasa NK, Gande A, Anusha M, Dar H, Baji DB. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. Cureus. 2023 Jan:15(1):e33293. doi: 10.7759/cureus.33293. Epub 2023 Jan 3     [PubMed PMID: 36606106]

Level 3 (low-level) evidence

[2]

Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope JE, Takeuchi T, Hyrich KL, Winthrop KL, Aletaha D, Stamm TA, Schoones JW, Landewé RBM. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases. 2023 Jan:82(1):95-106. doi: 10.1136/ard-2022-223365. Epub 2022 Nov 11     [PubMed PMID: 36368906]

Level 1 (high-level) evidence

[3]

Kedra J, Lafourcade A, Combe B, Dougados M, Hajage D, Fautrel B. Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD open. 2022 May:8(1):. doi: 10.1136/rmdopen-2021-002040. Epub     [PubMed PMID: 35534053]

[4]

Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, Poullis A, Patel K. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline gastroenterology. 2024 Jan:15(1):59-69. doi: 10.1136/flgastro-2023-102400. Epub 2023 Sep 14     [PubMed PMID: 38487554]

Level 3 (low-level) evidence

[5]

Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology. 2024 Feb:20(2):101-115. doi: 10.1038/s41584-023-01062-9. Epub 2024 Jan 12     [PubMed PMID: 38216757]

[6]

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research. 2021 Jul:73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8     [PubMed PMID: 34101387]

[7]

Zhang Y, Du K, Wu B, Wang Y, Wei H, Feng X, Xu J, Xu P, Huang J. Predictors of Boolean2.0 remission in rheumatoid arthritis identified using smart disease management system data. Scientific reports. 2025 Apr 21:15(1):13676. doi: 10.1038/s41598-025-97084-2. Epub 2025 Apr 21     [PubMed PMID: 40258859]

[8]

Peterson E, Gallagher MK, Wilbur J. Rheumatoid Arthritis: Diagnosis and Management for the Family Physician. American family physician. 2024 Nov:110(5):515-526     [PubMed PMID: 39556634]

[9]

Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021 Oct 23:10(11):. doi: 10.3390/cells10112857. Epub 2021 Oct 23     [PubMed PMID: 34831081]

Level 3 (low-level) evidence

[10]

Heckert SL, Maassen JM, Nevins I, Baudoin P, Steup-Beekman GM, Huizinga TWJ, Bergstra SA, Allaart CF. Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies. Rheumatology (Oxford, England). 2025 Mar 1:64(3):1052-1059. doi: 10.1093/rheumatology/keae212. Epub     [PubMed PMID: 38561181]

Level 2 (mid-level) evidence

[11]

Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the rheumatic diseases. 2024 Jan 2:83(1):15-29. doi: 10.1136/ard-2023-224762. Epub 2024 Jan 2     [PubMed PMID: 37827694]

[12]

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.). 2021 Jul:73(7):1108-1123. doi: 10.1002/art.41752. Epub 2021 Jun 8     [PubMed PMID: 34101376]

[13]

Jin S, Zhao J, Li M, Zeng X. New insights into the pathogenesis and management of rheumatoid arthritis. Chronic diseases and translational medicine. 2022 Dec:8(4):256-263. doi: 10.1002/cdt3.43. Epub 2022 Sep 21     [PubMed PMID: 36420174]

[14]

Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid Arthritis. StatPearls. 2025 Jan:():     [PubMed PMID: 28723028]

[15]

Bauhammer J, Fiehn C. [Rheumatoid Arthritis]. Deutsche medizinische Wochenschrift (1946). 2025 Apr:150(9):508-520. doi: 10.1055/a-2286-6620. Epub 2025 Apr 8     [PubMed PMID: 40199468]

[16]

Conley B, Bunzli S, Bullen J, O'Brien P, Persaud J, Gunatillake T, Nikpour M, Grainger R, Barnabe C, Lin I. What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clinical rheumatology. 2023 Sep:42(9):2267-2278. doi: 10.1007/s10067-023-06654-0. Epub 2023 Jun 9     [PubMed PMID: 37291382]

Level 1 (high-level) evidence

[17]

Soriano ER, Coates LC, Kavanaugh A. GRAPPA 2021 Treatment Recommendations for Psoriatic Arthritis. The Journal of rheumatology. 2023 Nov:50(Suppl 2):31-32. doi: 10.3899/jrheum.2023-0522. Epub 2023 Jul 7     [PubMed PMID: 37419619]

[18]

Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernández-Ávila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, O'Sullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A, GRAPPA Treatment Recommendations domain subcommittees. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature reviews. Rheumatology. 2022 Dec:18(12):734. doi: 10.1038/s41584-022-00861-w. Epub     [PubMed PMID: 36216924]

[19]

Englert KA, Dyduch G, Kłosowicz A, Spałkowska M, Jaworek AK, Migacz-Gruszka K, Jarosz-Chudek A, Mercuri SR, Szpor J, Mazzoccoli G, Damiani G, Wojas-Pelc A. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus. Medicina (Kaunas, Lithuania). 2023 Nov 17:59(11):. doi: 10.3390/medicina59112022. Epub 2023 Nov 17     [PubMed PMID: 38004071]

[20]

Peng-Cheng L, Meng-Na L, Jian-Bin L, Shu-Jiao Y, Wu R. Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus. Heliyon. 2024 May 15:10(9):e30393. doi: 10.1016/j.heliyon.2024.e30393. Epub 2024 Apr 27     [PubMed PMID: 38711668]

[21]

Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Frontiers in immunology. 2022:13():1051609. doi: 10.3389/fimmu.2022.1051609. Epub 2022 Dec 12     [PubMed PMID: 36578492]

Level 1 (high-level) evidence

[22]

Hanoodi M, Mittal M. Methotrexate. StatPearls. 2026 Jan:():     [PubMed PMID: 32310574]

[23]

Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint bone spine. 2019 May:86(3):301-307. doi: 10.1016/j.jbspin.2018.07.004. Epub 2018 Aug 3     [PubMed PMID: 30081197]

[24]

Rubio-Romero E, Díaz-Torné C, Moreno-Martínez MJ, De-Luz J. Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. BMC rheumatology. 2024 Mar 5:8(1):11. doi: 10.1186/s41927-024-00381-y. Epub 2024 Mar 5     [PubMed PMID: 38444043]

Level 2 (mid-level) evidence

[25]

Padda IS, Goyal A. Leflunomide. StatPearls. 2025 Jan:():     [PubMed PMID: 32491731]

[26]

Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. Anais brasileiros de dermatologia. 2023 Sep-Oct:98(5):656-677. doi: 10.1016/j.abd.2023.03.001. Epub 2023 May 23     [PubMed PMID: 37230920]

[27]

In 't Veld AE, Jansen MAA, Ciere LCA, Moerland M. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19. Journal of immunology research. 2021:2021():6659410. doi: 10.1155/2021/6659410. Epub 2021 Mar 9     [PubMed PMID: 33763494]

[28]

Domańska-Poboża J, Wisłowska M. Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective. Reumatologia. 2025:63(2):116-130. doi: 10.5114/reum/195012. Epub 2025 Feb 10     [PubMed PMID: 40485948]

Level 3 (low-level) evidence

[29]

Mohamed Ahamada M, Wu X. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis. Clinical and experimental rheumatology. 2023 Sep:41(9):1882-1900. doi: 10.55563/clinexprheumatol/2xjg0d. Epub 2023 Mar 7     [PubMed PMID: 36912326]

Level 1 (high-level) evidence

[30]

Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics. 2022 May 6:14(5):. doi: 10.3390/pharmaceutics14051001. Epub 2022 May 6     [PubMed PMID: 35631587]

Level 3 (low-level) evidence

[31]

Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, Gregoriou S. The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. Journal of clinical medicine. 2022 Jul 29:11(15):. doi: 10.3390/jcm11154431. Epub 2022 Jul 29     [PubMed PMID: 35956047]

Level 1 (high-level) evidence

[32]

Hebing RC, Lin M, Bulatovic Calasan M, Muller IB, Mahmoud S, Heil S, Struys EA, van den Bemt BJ, Twisk JW, Lems W, Nurmohamed MT, Jansen G, de Jonge R. Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial. Annals of the rheumatic diseases. 2023 Apr:82(4):460-467. doi: 10.1136/ard-2022-223398. Epub 2022 Dec 21     [PubMed PMID: 36543526]

[33]

Tanaka Y, Okuda K, Takeuchi Y, Katayama K, Haji Y, Yamanishi Y, Tribanek M, Guimbal-Schmolck C, Takeuchi T. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Modern rheumatology. 2023 Jul 4:33(4):680-689. doi: 10.1093/mr/roac103. Epub     [PubMed PMID: 36053757]

[34]

Vermeer E, Hebing RCF, van de Meeberg MM, Lin M, de Meij TGJ, Struys EA, Jansen G, Nurmohamed MT, Ćalasan MB, de Jonge R. Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature. Current rheumatology reports. 2023 Dec:25(12):276-284. doi: 10.1007/s11926-023-01116-7. Epub 2023 Sep 28     [PubMed PMID: 37768405]

[35]

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases. 2023 Jan:82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10     [PubMed PMID: 36357155]

[36]

Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, Förger F, Fischer-Betz R, Molto A, Tincani A, Pasquier E, Marin B, Elefant E, Salmon J, Bermas BL, Sammaritano L, Clowse MEB, Chambers C, Buyon J, Inoue SA, Agmon-Levin N, Aguilera S, Emadi SA, Andersen J, Andrade D, Antovic A, Arnaud L, Christiansen AA, Avcin T, Badreh-Wirström S, Bertsias G, Bini I, Bobirca A, Branch W, Brucato A, Bultink I, Capela S, Cecchi I, Cervera R, Chighizola C, Cobilinschi C, Cuadrado MJ, Dey D, Etomi O, Espinosa G, Flint J, Fonseca JE, Fritsch-Stork R, Gerosa M, Glintborg B, Skorpen CG, Goulden B, Graversgaard C, Gunnarsson I, Gupta L, Hetland M, Hodson K, Hunt BJ, Isenberg D, Jacobsen S, Khamashta M, Levy R, Linde L, Lykke J, Meissner Y, Moore L, Morand E, Navarra S, Opris-Belinski D, Østensen M, Ozawa H, Perez-Garcia LF, Petri M, Pons-Estel GJ, Radin M, Raio L, Rottenstreich A, Ruiz-Irastorza G, Tunjić SR, Rygg M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou M, Troldborg A, Vinet E, Vojinovic J, Voss A, Wallenius M, Andreoli L. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet. Rheumatology. 2023 Sep:5(9):e501-e506. doi: 10.1016/S2665-9913(23)00215-1. Epub 2023 Aug 21     [PubMed PMID: 38251494]

Level 3 (low-level) evidence

[37]

Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, Gladman DD, Molad Y, Nalli C, Mokbel A, Tincani A, Urowitz M, Bay C, van Noord M, Petri M. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus science & medicine. 2022 Mar:9(1):. doi: 10.1136/lupus-2021-000651. Epub     [PubMed PMID: 35318256]

Level 1 (high-level) evidence

[38]

Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, Andreoli L, Wirström SB, Boyadhzieva V, Chambers C, Costedoat-Chalumeau N, Dolhain RJEM, Fischer-Betz R, Giles I, Gøtestam-Skorpen C, Hoeltzenbein M, Marchiori F, Mayer-Pickel K, Molto A, Nelson-Piercy C, Nielsen OH, Tincani A, Wallenius M, Zbinden A, Meissner Y, Finckh A, Förger F. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the rheumatic diseases. 2025 Jun:84(6):910-926. doi: 10.1016/j.ard.2025.02.023. Epub 2025 Apr 26     [PubMed PMID: 40287311]

[39]

van Gendt J, Emaus R, Visschedijk MC, Touw DJ, Bouwknegt DG, de Leeuw K, Prins JR, Malik P, Mian P. Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review. Clinical pharmacokinetics. 2024 May:63(5):589-622. doi: 10.1007/s40262-024-01370-7. Epub 2024 Apr 7     [PubMed PMID: 38583128]

Level 1 (high-level) evidence

[40]

Membrive-Jiménez C, Sánchez-Piedra C, Martínez-González O, García-González J, Expósito-Pérez L, Bohórquez-Heras C, Campos-Fernández C, Sanchez-Alonso F, Cáliz-Cáliz R, Castrejón-Fernández I. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry. Reumatologia clinica. 2023 Nov:19(9):500-506. doi: 10.1016/j.reumae.2023.02.005. Epub     [PubMed PMID: 37945183]

[41]

Goulden B, Chua N, Parker E, Giles I. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology (Oxford, England). 2022 Oct 6:61(10):3902-3906. doi: 10.1093/rheumatology/keac141. Epub     [PubMed PMID: 35258557]

Level 1 (high-level) evidence

[42]

Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Current opinion in rheumatology. 2020 May:32(3):238-246. doi: 10.1097/BOR.0000000000000710. Epub     [PubMed PMID: 32205567]

Level 3 (low-level) evidence

[43]

Ryu RJ, Easterling TR, Caritis SN, Venkataramanan R, Umans JG, Ahmed MS, Clark S, Kantrowitz-Gordon I, Hays K, Bennett B, Honaker MT, Thummel KE, Shen DD, Hebert MF. Prednisone Pharmacokinetics During Pregnancy and Lactation. Journal of clinical pharmacology. 2018 Sep:58(9):1223-1232. doi: 10.1002/jcph.1122. Epub 2018 May 7     [PubMed PMID: 29733485]

[44]

Zarén P, Turesson C, Giwercman A. Methotrexate use among men-association with fertility and the perinatal health of their children: a Swedish nationwide register study. Fertility and sterility. 2023 Sep:120(3 Pt 2):661-669. doi: 10.1016/j.fertnstert.2023.05.005. Epub 2023 Jul 1     [PubMed PMID: 37395690]

[45]

. Methotrexate. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643544]

[46]

Hoofnagle JH. Leflunomide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31644034]

[47]

. Tocilizumab. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643567]

[48]

. Upadacitinib. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 34633781]

[49]

. Baricitinib. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643344]

[50]

Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clinical pharmacology and therapeutics. 2003 Jul:74(1):85-94     [PubMed PMID: 12844139]

[51]

Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug safety. 2025 Aug:48(8):943-952. doi: 10.1007/s40264-025-01535-8. Epub 2025 Mar 23     [PubMed PMID: 40121611]

Level 3 (low-level) evidence

[52]

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun:123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16     [PubMed PMID: 26992838]

[53]

Yusuf IH, Charbel Issa P, Ahn SJ. Hydroxychloroquine-induced Retinal Toxicity. Frontiers in pharmacology. 2023:14():1196783. doi: 10.3389/fphar.2023.1196783. Epub 2023 May 30     [PubMed PMID: 37324471]

[54]

Yusuf IH, Han RC, Downes SM, Sharma SM. The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom. Eye (London, England). 2024 Oct:38(14):2796-2804. doi: 10.1038/s41433-024-03168-0. Epub 2024 Jul 31     [PubMed PMID: 39085597]

[55]

Hu Q, Wang H, Xu T. Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning. Journal of clinical medicine. 2023 Feb 17:12(4):. doi: 10.3390/jcm12041599. Epub 2023 Feb 17     [PubMed PMID: 36836131]

[56]

Andronache IT, Şuţa VC, Şuţa M, Ciocodei SL, Vladareanu L, Nicoara AD, Arghir OC. Better Safe than Sorry: Rheumatoid Arthritis, Interstitial Lung Disease, and Medication-A Narrative Review. Biomedicines. 2023 Jun 19:11(6):. doi: 10.3390/biomedicines11061755. Epub 2023 Jun 19     [PubMed PMID: 37371850]

Level 3 (low-level) evidence

[57]

Havele SA, Ellis A, Chaitoff A, Khanna U, Parambil J, Langford CA, Fernandez AP. Safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in patients taking methotrexate. Journal of the American Academy of Dermatology. 2021 Jan:84(1):166-168. doi: 10.1016/j.jaad.2020.04.040. Epub 2020 Apr 19     [PubMed PMID: 32320772]

[58]

Harimohan H, Huynh Q, Yasonova M, Moosavi L, Khamlong M, Garcia Pacheco I. Two Consecutive Days of Low-Dose Methotrexate Toxicity: A Diagnostic Challenge. Cureus. 2025 Jun:17(6):e86023. doi: 10.7759/cureus.86023. Epub 2025 Jun 14     [PubMed PMID: 40520835]

[59]

Lian BS, Busmanis I, Lee HY. Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo. Annals of the Academy of Medicine, Singapore. 2018 Nov:47(11):492-493     [PubMed PMID: 30578426]

[60]

Devarbhavi H, Ghabril M, Barnhart H, Patil M, Raj S, Gu J, Chalasani N, Bonkovsky HL. Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries. Liver international : official journal of the International Association for the Study of the Liver. 2022 Jun:42(6):1323-1329. doi: 10.1111/liv.15189. Epub 2022 Feb 15     [PubMed PMID: 35129282]

[61]

Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2016 Jun:75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28     [PubMed PMID: 26318385]

[62]

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA, ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. The New England journal of medicine. 2022 Jan 27:386(4):316-326. doi: 10.1056/NEJMoa2109927. Epub     [PubMed PMID: 35081280]

[63]

Huss V, Bower H, Wadström H, Frisell T, Askling J, ARTIS group. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford, England). 2022 May 5:61(5):1810-1818. doi: 10.1093/rheumatology/keab570. Epub     [PubMed PMID: 34324640]

[64]

Park JW, Curtis JR, Jun KI, Kim TM, Heo DS, Ha J, Suh KS, Lee KW, Lee H, Yang J, Kim MJ, Choi Y, Lee EB. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab. Chest. 2022 May:161(5):1201-1210. doi: 10.1016/j.chest.2021.11.007. Epub 2021 Nov 14     [PubMed PMID: 34788668]

[65]

Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immunity, inflammation and disease. 2023 Feb:11(2):e780. doi: 10.1002/iid3.780. Epub     [PubMed PMID: 36840482]

Level 1 (high-level) evidence

[66]

Tao D, Wang H, Xia F, Ma W. Pancytopenia Due to Possible Drug-Drug Interactions Between Low-Dose Methotrexate and Proton Pump Inhibitors. Drug, healthcare and patient safety. 2022:14():75-78. doi: 10.2147/DHPS.S350194. Epub 2022 May 17     [PubMed PMID: 35607639]

[67]

Skoloda D, Newman M, Norman H, Ziggas JE, Ambinder RF. Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients. JCO oncology practice. 2024 May:20(5):673-677. doi: 10.1200/OP.23.00792. Epub 2024 Feb 21     [PubMed PMID: 38382007]

[68]

Xu Q, Li Z, Ding T, Qiu X, Wu Z. Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate. Annals of hematology. 2025 Jan:104(1):457-465. doi: 10.1007/s00277-024-06146-4. Epub 2024 Dec 18     [PubMed PMID: 39690250]

Level 2 (mid-level) evidence

[69]

Mcknight M, Cutshall BT, Sakaan S, Al Hommos NA, Wells DA. Hydroxychloroquine-Induced Hypoglycemia in a Patient Without Diabetes. Journal of pharmacy practice. 2024 Oct:37(5):1205-1208. doi: 10.1177/08971900241228762. Epub 2024 Jan 19     [PubMed PMID: 38240599]

[70]

Korzec J, Strausbaugh R, Mikolay JJ Jr, Churchwell MD. Rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient: A missed opportunity for pharmacist involvement. Journal of the American Pharmacists Association : JAPhA. 2024 May-Jun:64(3):102016. doi: 10.1016/j.japh.2024.01.012. Epub 2024 Jan 23     [PubMed PMID: 38272309]

[71]

Cao Z, Wang Z, Zhang Q, Zhang W, Zheng L, Hu W. Physiologically Based Pharmacokinetic Modeling of Tofacitinib: Predicting Drug Exposure and Optimizing Dosage in Special Populations and Drug-Drug Interaction Scenarios. Pharmaceuticals (Basel, Switzerland). 2025 Mar 18:18(3):. doi: 10.3390/ph18030425. Epub 2025 Mar 18     [PubMed PMID: 40143201]

[72]

Tyczyńska KM, Augustyniak-Bartosik H, Świerkot J. Rheumatoid arthritis - medication dosage in chronic kidney disease. Reumatologia. 2023:61(6):481-491. doi: 10.5114/reum/177005. Epub 2024 Jan 18     [PubMed PMID: 38322106]

[73]

Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, Wendling D, Pham T, Gottenberg JE, Mariette X, Morel J, French Society of Rheumatology and the investigators participating in AIR-PR, ORA and REGATE registries. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford, England). 2022 Mar 2:61(3):953-962. doi: 10.1093/rheumatology/keab438. Epub     [PubMed PMID: 33993216]

[74]

Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, Shi R, Flower A, Picard H, Stein Gold L. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome. American journal of clinical dermatology. 2023 Sep:24(5):809-820. doi: 10.1007/s40257-023-00783-7. Epub 2023 Jun 14     [PubMed PMID: 37316690]

Level 1 (high-level) evidence

[75]

Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL Jr, Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis care & research. 2023 Mar:75(3):449-464. doi: 10.1002/acr.25045. Epub 2023 Jan 4     [PubMed PMID: 36597813]

[76]

Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-Diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Polverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Annals of the rheumatic diseases. 2023 Jun:82(6):742-753. doi: 10.1136/ard-2022-223335. Epub 2022 Nov 3     [PubMed PMID: 36328476]

[77]

Ajeganova S, Andersson M, Forslind K, Gjertsson I, Nyhäll-Wåhlin BM, Svensson B, Hafström I. Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years. BMC rheumatology. 2023 Aug 7:7(1):23. doi: 10.1186/s41927-023-00347-6. Epub 2023 Aug 7     [PubMed PMID: 37550762]

[78]

Atallah E, Grove JI, Crooks C, Burden-Teh E, Abhishek A, Moreea S, Jordan KM, Ala A, Hutchinson D, Aspinall RJ, Murphy R, Aithal GP. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of hepatology. 2023 May:78(5):989-997. doi: 10.1016/j.jhep.2022.12.034. Epub 2023 Jan 23     [PubMed PMID: 36702175]

[79]

Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, Alenazy RH, Alhumaidi NT, Alhulayfi DH, Alotaibi YB, Alhumaidan SS, Alhaddad ZA, Humadi AA, Alzahrani SA, Alobaid RH. Overview of Methotrexate Toxicity: A Comprehensive Literature Review. Cureus. 2022 Sep:14(9):e29518. doi: 10.7759/cureus.29518. Epub 2022 Sep 23     [PubMed PMID: 36312688]

Level 3 (low-level) evidence

[80]

Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Canadian respiratory journal. 2013 May-Jun:20(3):153-5     [PubMed PMID: 23762881]

[81]

Cottin V, Bendstrup E, Bonniaud P, Nasser M, Spagnolo P, Valenzuela C, Kolb M. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. The European respiratory journal. 2021 Feb:57(2):. pii: 2100079. doi: 10.1183/13993003.00079-2021. Epub 2021 Feb 11     [PubMed PMID: 33574052]

Level 3 (low-level) evidence

[82]

Chang SH, Jung S, Chae JJ, Kim JY, Kim SU, Choi JY, Han HJ, Kim HT, Kim HJ, Kim HJ, Park WY, Sparks JA, Lee EY, Lee JS. Therapeutic single-cell landscape: methotrexate exacerbates interstitial lung disease by compromising the stemness of alveolar epithelial cells under systemic inflammation. EBioMedicine. 2024 Oct:108():105339. doi: 10.1016/j.ebiom.2024.105339. Epub 2024 Sep 19     [PubMed PMID: 39303666]

[83]

Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, O'Dell JR, Schmajuk G, Werth VP, Melles RB, Marmor MF. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis & rheumatology (Hoboken, N.J.). 2021 Jun:73(6):908-911. doi: 10.1002/art.41683. Epub 2021 Apr 26     [PubMed PMID: 33559327]

[84]

Li N, Gou ZP, Du SQ, Zhu XH, Lin H, Liang XF, Wang YS, Feng P. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clinical rheumatology. 2022 Mar:41(3):677-688. doi: 10.1007/s10067-021-06003-z. Epub 2022 Jan 7     [PubMed PMID: 34993729]

Level 1 (high-level) evidence

[85]

Dhillon GS, Chauhan S, Jalal Y, Ghobrial Y, Ahmed B. Low-Dose Methotrexate Toxicity Presenting as Pancytopenia. Cureus. 2022 Dec:14(12):e32494. doi: 10.7759/cureus.32494. Epub 2022 Dec 13     [PubMed PMID: 36654616]

[86]

Bhargava M, Kopp CR, Naidu S, Dhibar DP, Saroch A, Khadwal A, Narang T, Jain S, Khullar A, Leishangthem B, Sharma A, Kumar S, Sharma S, Jain S, Dhir V. Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity - a randomized controlled trial. Arthritis research & therapy. 2023 May 19:25(1):82. doi: 10.1186/s13075-023-03054-2. Epub 2023 May 19     [PubMed PMID: 37208770]

Level 1 (high-level) evidence

[87]

Kala J, Nelson R, Drudge C, Zhou A, Ward S, Bourque M. Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis. ClinicoEconomics and outcomes research : CEOR. 2023:15():165-179. doi: 10.2147/CEOR.S397154. Epub 2023 Mar 8     [PubMed PMID: 36919083]

[88]

Kuchinskaya EM, Chikova IA, Kostik MM. Case report: Sulfasalazine-induced hypersensitivity. Frontiers in medicine. 2023:10():1140339. doi: 10.3389/fmed.2023.1140339. Epub 2023 May 24     [PubMed PMID: 37293296]

Level 3 (low-level) evidence

[89]

Khelghati F, Rahmanian M, Eghbal E, Seghatoleslami ZS, Goudarzi M, Keramatinia A, Ong CW, Goletti D, D'Ambrosio L, Centis R, Nasiri MJ, Migliori GB. Risk of tuberculosis disease in patients receiving TNF-α antagonist therapy: A meta-analysis of randomized controlled trials. New microbes and new infections. 2024 Dec:62():101533. doi: 10.1016/j.nmni.2024.101533. Epub 2024 Nov 16     [PubMed PMID: 39639969]

Level 1 (high-level) evidence

[90]

Yokota H, Hoshida Y, Watanabe K, Yamada T. Progressive multifocal leukoencephalopathy associated with rituximab treatment. Journal of neurosciences in rural practice. 2024 Apr-Jun:15(2):396-398. doi: 10.25259/JNRP_434_2023. Epub 2024 Feb 7     [PubMed PMID: 38746524]